

*Original*

## **Genetic Analysis of *TP53* Gene Mutations in Exon 4 and Exon 8 among Esophageal Cancer Patients in Sudan**

Sulafa Mohamed Eltaher<sup>1\*</sup>, Abeer Babiker Idris<sup>2,3</sup>, Mahmoud A. H<sup>4</sup>, Mawadah Yousif Mohamed Yousif<sup>4</sup>, Muzamil M. Abdel Hamid<sup>4</sup>, Kamal Elzaki Elsiddig<sup>5</sup>, Galal Mohammed Yousif<sup>6</sup>, Mohamed A. Hassan<sup>3,7</sup>

<sup>1</sup>The Academy of Health Sciences, the Republic of Sudan Federal Ministry of Health, Khartoum, Sudan

<sup>2</sup>Department of medical microbiology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan. <sup>3</sup>Applied Bioinformatics Center, Africa City of Technology, Khartoum, Sudan

<sup>4</sup>Department of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of

Khartoum, Khartoum, Sudan. <sup>5</sup>Department of Surgery, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. <sup>6</sup>Faculty of Pharmacy, Alrebat University, Khartoum, Sudan

<sup>7</sup>Department of Bioinformatics, DETAGEN Genetic Diagnostics Center, Kayseri, Turkey

\* **Corresponding author:** Sulafa Mohamed Eltaher, Assistant Professor. The Academy of Health Sciences, The Republic of Sudan Federal Ministry of Health, Khartoum, Sudan. Email: [Sulafaeltaher@hotmail.com](mailto:Sulafaeltaher@hotmail.com).

**Received:** 1 September 2022

**Accepted:** 10 September 2022

### **Abstract**

**Background:** Esophageal Carcinoma (EC) represents the first rank among all gastrointestinal cancers in Sudan. There are few publications in which there is an absence of literature about the molecular pathogenesis of EC considering TP53 gene from Sudanese population.

**Aims:** In this study we performed the expression analysis on p53 protein level by immunohistochemical staining and examined its overexpression with p53 mutations in exons 4 and 8 among esophageal cancer patients in Sudan.

**Material and Methods:** Fixed tissue with 10% buffered formalin was stained by Hematoxylin and Eosin (H&E), Alcian blue- Periodic Acid Schiff (PAS) and immunohistochemistry stain. PCR-

RFLP was used to study the frequencies of p53 codon 72 R/P polymorphism. Conventional PCR and Sanger sequencing were applied for exon 4 and exon 8. Then detection and functional analysis of SNPs and mutations were performed using various bioinformatics tools.

**Results:** Nuclear accumulations for p53 protein was detected in all of the esophageal examined carcinomas, while no accumulations were observed in normal control sections. Four patients that were immune-positive for p53 showed no mutations in p53 gene (exon4 and exon8). The incidence of the homozygous mutant variant Pro/Pro was higher in esophageal cancerous patients comparing to healthy control subjects 20(71.4%) vs. 1(10%), respectively ( $p=0.0026$ ). In exon 4, no mutation was detected other than NG\_017013.2:g. 16397C>G. While in exon 8, g.18783-18784AG>TT, g.18803A>C, g.18860A>C, g.18845A>T and g.18863\_18864 InsT were observed.

**Conclusion:** We found a significant association between the overexpression of TP53 protein and mutations in exon 4 and 8. A silent mutation P301P was detected in all of examined cases. Two patients who were diagnosed with small cell sarcoma shared the same mutations in exon 8. Further studies with a larger sample size are required to demonstrate the usefulness of these mutations in the screening of EC especially SCCE.

**Key words:** Esophageal carcinoma, Small cell carcinoma, SNPs, functional analysis, in silico tools.

## Introduction

Esophageal Carcinoma (EC) is the eighth most common diagnosed cancer worldwide and the sixth leading cause of cancer related mortality (1-3). EC primarily happens in one of two forms. The first is the esophageal squamous cell carcinoma (ESCC) which is more prevalent in developing countries, arising from the stratified squamous epithelial lining of the organ. The second is esophageal adenocarcinoma (EAC) that is a distal esophageal cancer arising from a metaplastic transformation of the native esophageal squamous epithelium into columnar epithelium due to known risk factors such as obesity, smoking, gastroesophageal reflux and Barrett's esophagus (BE) (4-6).

ESCC is mainly associated with multiple factors such as smoking, alcohol consumption, hot tea drinking, red meat consumption, poor oral health, low intake of fresh fruit and vegetables and low socioeconomic status. Recently, there has been an increase in the incidence of EAC, especially in developed countries (4, 7, 8). This increase could be due to multiple factors, such as environmental factors together with existing genetic susceptibility factors (9). Sarcomas and small cell carcinomas usually constitute less than 1-2% of all esophageal cancers (10). In a logical

attempt to understand the remarkable diversity of neoplastic diseases, Hanahan and Weinberg have proposed eight hallmarks of cancer, moreover they added two enabling characteristics that make the acquisition of these hallmarks possible; genome instability and mutation, and tumor-promoting inflammation(11, 12). Knowing about these concepts may lead to develop new approaches to treat human cancers. Many studies have suggested that the polymorphisms in functionally critical genes may be involved in esophageal carcinoma (13). The most important genes are those which act as anti-oncogenesis. Loss of function for these genes may be even more important than proto-oncogene/oncogene activation for the process of esophageal oncogenesis (14). The most important tumor suppressor gene are reported widely in association with different types of cancer is *p53* gene (15).

*TP53* gene (ID: 7157, MIM: 191170) is often referred to as “the guardian” of the human genome.

It is mapped on 17p13 and composed of 11 exons (~20 KB) encoding a nuclear p53 protein of 393 amino acids (15-17). This regulatory protein controls the expression of hundreds of genes and noncoding RNAs, as well as the RNA processing complexes

activity. Also, p53 is involved in the checkpoint at the G1/S boundary of cell growth cycle and prevents the multiplication of damaged cells (16, 18-20). However, the p53 protein has others biological functions such as senescence, DNA metabolism, angiogenesis, cellular differentiation, and the immune response (15).

Single nucleotide polymorphisms (SNPs) of TP53 gene are expected to cause measurable perturbation on p53 function. These genetic variants in TP53 are implicated in the development of cancer because they influence cell cycle progression, apoptosis and DNA repair (15). At least 85 SNPs are reported on TP53. The common missense (nonsynonymous) polymorphism occurs at codon 72 of exon 4 in the transactivation proline-rich domain of the protein where either CCC encodes proline or CGC encodes arginine (TP53 Arg72Pro, rs 1042522) (21). Some studies have investigated the association of Arg72Pro polymorphism with different kinds of cancers such as esophageal (22), gastric (15), colorectal (23), lung (24), cervical and breast cancer (25).

In Sudan, EC is a growing problem. An earlier study conducted in Khartoum during the period 1965 to 1974, reported that the incidence of EC was 1.4% of all malignant

tumors (26). In contrast, a study conducted in Gezira province in central Sudan during the period from January 2005 to December 2006 revealed that 9.6% of patients referred for endoscopy proved to have esophageal cancer (27). Now EC represents the first rank among all gastrointestinal (GI) cancers in Sudan (10, 28). Unfortunately, there is a deep absence of literature talking about the molecular pathogenesis of EC considering p53 gene in Sudan. Therefore, here we investigated the association between the over expression of TP53 protein and mutation in exon 4 and exon 8, then studied their roles in tumorigenesis using in silico tools. To the best of our knowledge, this study, is the first study in Sudan to analyze the genetic alterations in exon 4 and exon 8 of patients with small cell sarcoma of esophagus (14.29% of our patients).

## **Materials and methods**

### **Study population**

This study included 24 primary esophagus carcinoma patients. All patients were recruited from the department of endoscopy. Tumor types and stages were determined by experienced pathologists. Blood samples of participants aged 20 years and gender-matched cases with no signs of any malignancy were collected as controls. The

mean age of both patients and control groups was 50 years old and 15 patients and 14 controls were >50 years old. Data on all esophagus carcinoma patients were obtained from personal interviews with patients and/or co-patients, medical records and pathology reports. The data collected included gender, age, dwelling, tumor location, symptoms and risk factor of exposure. The demographic characteristics of the cases and controls; and clinico-pathological characteristics of cases are summarized in Table 1 and Table 2.

All patients and/or co-patients were informed about the study and their consent to participate in this study was obtained. This study was approved by the Ethics Committee of Tropical Diseases and Sudan Academy. Informed consent was obtained from the participants.

### **Histological analysis**

Fixed tissue with 10% buffered formalin was stained by Hematoxylin and Eosin (H&E), carcinoma diagnosis was confirmed by pathologist who looked for the degree of histological differentiation; well, moderate, poor, or undifferentiated tumors. The anatomic subsides were categorized as first and third esophagus, the middle third, lower third and junctional area. Also, Alcian blue-Periodic Acid Schiff (PAS) stain was used

to differentiate between neutral and acetic muco-substances. We used an internal control of normal tissue mucin control.

### **Immunohistochemistry**

TP53 immunohistochemistry was performed with the mouse monoclonal antibody Do-7 (Dako, Glostrup, Denmark), according to standard protocols.

### **Molecular Genetics Analysis**

#### **DNA extraction**

DNA was extracted from fresh tissue by using Guanidine chloride method as previously described by Coleman *et al* (29). The Concentration of DNA was determined by Spectrophotometer.

#### **Polymerase Chain Reaction (PCR)**

Extracted DNA was amplified for the TP53 gene. The primers for exon 4 were: forward, 5'TCCCCCTTGCCGTCCCAA3'; reverse, 5'CGTGCAAGTCACAGACTT3' and for exon 8 were Forward: 5'GGGAGTAGATGGAGCCTGGT3'; reverse:

5'GCTTCTTGTCCTGCTTGCTT3' (30).

Exon 4 and 8 of the p53 gene were amplified separately by incubating on the cycler for 10min at 94°C for initial denaturation followed by 35 cycles at 90°C for 30s, 55°C for 30s and 72°C for 1min. The final extension step was 72°C for 7min. After that prepare gel run (Agarose 1.5 gm) run the

PCR product on agarose gel visualize the PCR product under UV light.

### **Restriction fragment length polymorphism (PCR-RFLP) analysis**

For genotyping of p53 for the codon 72 polymorphism, 10µl of enzyme *BstUI* were added and incubated overnight at 37°C. Then the digested product was separated on 3% agarose gel with ethidium bromide and photographed with an Ultra Violet Product Image Store System (30).

### **DNA sequencing**

Out of 48 PCR products, 13 patients and 10 controls were sent for Sanger dideoxy sequencing, including both forward and reverse nucleotide sequencing, which performed by Macrogen Company (Seoul, South Korea).

### **Sequence analysis**

Sequence analysis was done by Finch TV program version 1.4.0 (31). The two chromatograms for each individual, (forward and reverse), were visualized and checked for quality; and The Basic Local Alignment Search Tool (BLAST; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>) was used to assess nucleotide and protein sequence similarities (32).

### **SNPs detection**

Gene Screen software (33) was used to search for mutations and SNPs in all ABI

trace files when compared with a reference sequence (*TP53* NCBI Reference Sequence: NG\_017013) (34) and calculating alleles frequencies. Then tested the sequences with the reference sequence. High similarity sequences (U94788) and (X54156), were obtained from NCBI database and added as control sequences. They were aligned to confirm the presence of nucleotide changes by using BioEdit software (35). Finally, by using online ExPASy translate tool (36), all tested sequences were translated to amino acid sequences and compared all together with reference sequence (ID:P04637) using BioEdit software.

### **Functional analysis of SNPs**

Selected SNP was predicted functionally by using four online soft wares:

- i) Sorting intolerant from tolerant (SIFT) software(37) which predicted if the SNP affects protein function based on sequence homology and the physical properties of amino acids.
- ii) Polymorphism Phenotyping v2 (PolyPhen-2) software (38) that predicted possible impact of the SNP on the structure and function of a human protein using straightforward physical and comparative considerations.

- iii) Project hope software (39) analyzes the effect of the SNP on the protein structure.
- iv) I-Mutant software (40) is used to assess the stability of the SNP involved protein.
- v) Predictor of Human Deleterious Single Nucleotide Polymorphisms (PhDSNP) (41) predicts the relatedness of SNP or mutation to a disease based on a single SVM trained and tested on protein sequence and profile information.

### Modeling (3D structure)

The protein sequence of *TP53* gene (ID:P04637) was sent to RaptorX Property, a web server,

(<http://raptorx2.uchicago.edu/StructurePropertyPred/predict/>) (42), to predict structure properties of these protein sequences. Then the 3D structures were visualized by UCSF Chimera (version 1.8) that is currently available within the Chimera package and available from the chimera website (<http://www.cgl.ucsf.edu/cimera>)(43).

### Statistical analysis

Results of *p53* codon 72 SNP among cancerous patients and controls were analyzed using X2 test.  $P < 0.05$  was considered statistically significant. Statistical analyses in this study were performed using GraphPad Prism (version 5.0).

**Table 1:** Demographic and clinic-pathological characteristics of esophageal cancer patients

Patient No.	Gender	Age	Residence	Tribe	Type of carcinoma	Tumor location	Degree of differentiation	Symptoms
1	Female	42	Om Badah	Jwamah	Squamous cell carcinoma	Upper part	Well differentiation	Chest pain and lose weight
2	Female	57	Bahry	Rofaha	Squamous cell carcinoma	Middle part	Well differentiation	hoarseness

3	Female	60	North Sudan	Mahass	carcinoma		Upper part	Poorly differentiation	Bleeding
4	Female	57	Khartoum	Magarbah	Squamous carcinoma	cell	Upper part	Well differentiation	Chronic cough
5	Male	74	Om Badah	Mahass	Small carcinoma	cell	Middle part	Well differentiation	Difficulty swallowing
6	Female	53	Atbarah	Mahass	adenocarcinoma		Lower part	Moderately differentiation	Weight loss chest pain
7	Male	56	Om Rowaba	Foor	adenocarcinoma		Middle part	Well differentiation	Vomiting difficulty swallowing
8	Male	37	North Darfour	Nobaa	Squamous carcinoma	cell	Upper part	Well differentiation	Hiccups weight loss
9	Female	75	Khartoum	Jaali	carcinoma		Middle part	Poorly differentiation	Vomiting and bleeding
10	Male	40	Kalakllah	Jaali	Squamous carcinoma	cell	Upper part	Well differentiation	Chest pain weight loss
11	Female	30	North Kordofan	Dar Hammed	adenocarcinoma		Lower part	Well differentiation	Chronic cough and bleeding
12	Male	42	Khartoum	Jaali	Squamous carcinoma	cell	Upper part	Moderately differentiation	Difficulty swallowing
13	Male	57	Om Dorman	Foor	Squamous carcinoma	cell	Upper part	Well differentiation	dysphagia
14	Male	77	Al-Jazirah	Jamooaie	adenocarcinoma		Lower part	Moderately differentiation	Weight loss vomiting
15	Male	55	Bahri	Shokri	adenocarcinoma		Lower part	Well differentiation	Difficulty swallowing weight loss
16	Male	65	Om durman	Jamooaie	carcinoma		Upper part	Poorly differentiation	Vomiting and bleeding
17	Male	53	North Darfour	Zaghawa	Squamous carcinoma	cell	Upper part	Well differentiation	Chronic cough and hoarseness
18	Male	35	Port Sudan	BaniAamer	Small carcinoma	cell	Middle part	Well differentiation	Chest pain, bleeding and cough
19	Male	40	Al-Jazirah	Zaghawah	Small carcinoma	cell	Middle part	Well differentiation	Chest pain, vomiting and weight loss
20	Male	57	Kosti	Jaafrah	Squamous carcinoma	cell	Upper part	Moderately differentiation	Bone pain and weight loss
21	Male	35	Al-Jazirah	Rofaie	Small carcinoma	cell	Middle part	Well differentiation	Difficulty swallowing
22	Male	53	Kasala	Hadandawa	Squamous carcinoma	cell	Upper part	Moderately differentiation	Cough and hoarseness
23	Female	37	Kasala	Baniamer	Squamous carcinoma	cell	Upper part	Well differentiation	Chest pain and difficulty swallowing
24	Male	79	Dongulah	Dongulawi	adenocarcinoma		Lower part	Well differentiation	Vomiting and weight loss
25	Male	75	Al-Jazirah	Rofaie	adenocarcinoma		Lower part	Well differentiation	Bleeding and vomiting
26	Male	70	Al-Jazirah	Oghili	adenocarcinoma		Lower part	Moderate differentiation	hoarseness
27	Female	70	port Sudan	Hadandawa	Squamous carcinoma	cell	Middle part	Poorly differentiation	Bone pain, dysphagia and dysphagia
28	Female	45	Al-mojlad	Barbari-Dahmiah	adenocarcinoma		Lower part	Well differentiation	Dysphagia and weight loss

**Table 2:** Demographic characteristics of healthy controls

Control No.	Gender	Age	Residence	Tribe
1	Male	35	North Darfor	Jamiaie

2	Female	50	Bahri	Mahasia
3	Female	48	Khartoum	Mahesia
4	Female	80	North State	Mahesia
5	Male	32	Senar	Jamiaie
6	Female	45	North Kordufan	Jamiaie
7	Male	78	Khartoum	Ababdah
8	Female	60	Khartoum	Magarbah
9	Male	60	Sinar	Hamar
10	Male	47	Om durman	Jafrah
11	Female	47	Al-Jazirah	Hasaniah
12	Female	28	Sinar	Jafrah
13	Female	42	Bahri	Jaali
14	Male	40	Khartoum	Jaali
15	Male	62	Khartoum	Jaali
16	Female	30	Sinar	Daishah
17	Male	55	Shandi	Jaali
18	Female	48	North State	Shigiah
19	Female	52	Shandi	Jaali
20	Female	46	Bahri	Robatab

## Results

### Histo-pathological results


The microscopic morphology of most slides (Hematoxylin and Eosin) at squamous cell carcinoma were moderately to well differentiated and showed pleomorphic variation in size and shape both in cells and nuclei; abnormal nuclear morphology hyperchromatic and contain an abundance of chromatin. Nuclear shape was variable with chromatin clumped and large nucleoli.

Large numbers of mitoses with higher proliferative activity appeared in abnormal locations within epithelium cells and stroma. Well and Moderately differentiated Squamous cell carcinoma showed some


bridges and nests of keratin pearls and also invasion into the submucosa. Poorly differentiated cell carcinoma revealed spreading of malignant cells (that seem like spindle cells) at the layers without differentiation and a highly bizarre mitotic division, therefore special stain PAS (periodic acid shiffs) was done to characterize carcinoma from sarcoma.

While in adenocarcinoma of esophagus, most tumors that were mucin-producing glandular tumors showed intestinal-type features with the morphology of preexisting metaplasticmucosa. The diffused type showed poorly differentiated adenocarcinoma with little or no discernible


gland formation, and tumor cells forming a diffuse sheet infiltrating between bundle of smooth muscle (Figure1-3).



**Figur1:** H&E for poorly differentiated carcinoma under the glands by light microscopy. Photograph showing high mitotic activity with abnormal mitotic figures (arrows) in an ESCC.




**Figure2:** showing a hyper proliferative epidermal cyst containing ghost cells and keratinized structures (K), accompanied by an acute stromal inflammatory reaction (I ) and epithelial structures.



**Figure3:** Alcian blue and PAS special stain to characterize the type of epithelial malignant.

### Immuno-histochemical *P53* over expression

Nuclear accumulations for p53 protein was detected in all of the esophageal carcinomas examined, as illustrated in Figure4. While no accumulations were observed in normal control sections. Four patients (patients 1, 3, 6 and 24) with immune-positive for *P53* showed no mutations in *P53* gene (exon 4 and exon8).




**Figure 4:** Showing immunohistochemistry expression for p53. No accumulation in mucosa but nuclear accumulation of p53 protein


### PCR-RFLP

*PCR-RFLP* was used to investigate the *p53* codon 72 SNP (dbSNP: rs1042522). The incidence of the homozygous mutant variant Pro/Pro was higher in esophageal cancerous patients compared to healthy control subjects 20(71.4%) vs. 1(10%), respectively ( $p=0.0026$ ) (Table3) (Figure 5).

**Table 3:** Genotype and allele frequency of the *p53* codon 72 SNP in esophageal cancerous patients and controls

	Case(n=28)	Control (n=10)	p-value
<b>Genotype</b>			0.0026
C/C	20(71.4%)	1(10%)	
C/G	4(14.28%)	3(30%)	
G/G	4(14.28%)	6(60%)	
<b>Allele</b>			<0.0001
C	44(78.57%)	5(25%)	
G	12(21.43%)	15(27%)	





**Figure 5:** a) Genotyping of *TP53* gene for the codon 72 polymorphism by PCR-RFLP. The wild type G/G genotype produced two bands: 205bp and 150 bp. G/C genotype produced three bands: 362bp, 205bp and 250bp. C/C genotype produced single band 362bp. b) Direct sequencing analysis of codon 72. c) 3D structure of TP53. Homology modeling of (NG\_017013) using raptorX online software.

### ***TP53* Nucleotide changes**

DNA Sequence analysis was done by Gene screen and BioEdit soft ware. The following sequence variants were observed in comparison with the reference sequence (NG\_017013). Mutations in the *p53* gene were found in 44%, 28% and 12% of esophageal squamous cell carcinomas, adenocarcinomas and small cell carcinomas, respectively. In exon 4, no mutation was detected other than NP\_000537.3:p.R72P. While in exon 8, g.18783-18784AG>TT p.E285E, g.18803A>C p.K291T, g.18860A>C p.P301P, g.18845A>T

p.K305M and g.18863-18864 InsT were observed (Figure 6).


Non-synonymous variants (R72P, K291T and K305M) were then functionally analyzed with SIFT, Polyphen-2, I-Mutant-3, and PhD-SNP to predict their pathological effects. The results are provided in Table 4. The 3D structure of the variant K291T was obtained using Project Hope software, (Figure 5C). While for R72P and K305M variants, we used Raptor X online software for prediction and Chimera for visualization (Figure 6).

**Table 4:** Functional analysis of SNPs obtained by various sequencing software's

SNP	SIFT		Polyphen-2		I-Mutant prediction	RI	PhD-SNP	
	Score	Prediction	Score	Prediction			Prediction	RI
R72P	0.52	Tolerated	0.083	Benign	Increase protein stability	2	Neural Polymorphism	7
K291T	0.00	deleterious	0.972	Probably damaging	Decrease protein stability	4	Neural Polymorphism	0
K305M	0.00	deleterious	1.000	Probably damaging	Decrease protein stability	2	Disease-related Polymorphism	3

SNP: single nucleotide polymorphism; RI: reliability index

## K291T



**Figure 6.** a) Illustrates the TP53 gene and genetic alterations observed in exon 8 for the studied population. E1 to E11 indicate exons 1 to 11. 7b) Shows the chromatogram of patients with small cell carcinoma. 5c) Illustrates BioEdit multiple sequences alignment determining mutations in exon 8. c) 3D structure of TP53. Homology modeling of (NG\_017013) using raptorX online software.

**Discussion**

Despite different genetic and epigenetic alterations involving oncogenes activation, genetic variations in *TP53* tumor suppressor represent the fundamental events related in both early and advanced stage of the esophageal tumor (44, 45). Previously, *TP53* mutations have been used as prognostic markers for patients' response to treatment and/or outcome (46, 47). In this study, we found a significant association between the accumulation of *p53* protein and mutations in exon 4 and 8. Although all patients with *p53* mutations were immune-positive, there were five patients who were immune-positive but had no mutations in exon 4 and 8. Two of whom with adenocarcinoma. Another study conducted by Doak *et al.* reported that the most immuno-positive adenocarcinoma cases had no demonstrable *p53* mutation and immunohistochemistry is a poor indicator of *p53* gene mutations (48). Thus, further investigations are required to determine the underlying mechanisms that are responsible for the accumulation of the *P53* protein.

In this study we evaluated the frequency of the *p53* Pro72Arg polymorphism in esophageal cancerous patients compared to healthy control subjects. Our findings exhibit a significant association between esophageal carcinoma and the Pro72 variant

of the Pro72Arg polymorphism of the *p53* gene. The Pro72 variant exhibits a higher level of G1 arrest and decreased apoptotic potential than the Arg72 variant (13, 15). A number of studies have suggested that the Pro allele or the Arg allele of *p53* codon 72 polymorphism had a significant effect on the risk of esophageal cancerogenesis while others did not demonstrate any significant association between them, as illustrated in Table 5 (Appendix 1).

The sequencing analysis of exon 4 for 28 patients, revealed no mutations or SNPs other than Arg72 Pro. While in exon 8, we performed sequencing for 5 patients and we found silent mutation P301P shared in all of them. Further studies with large sample size are required to demonstrate its usefulness in the screening of EC. The known hotspot mutations in exon 8 (p.C275Y, p.P278S and p. E298) (46) were not detected in this study.

The most important finding in this investigation was that two patients who were diagnosed with small cell carcinoma have beside the previously mentioned silent mutation P301P, a novel insertion mutation (18736\_18737 InsT) and missense mutation K305M. Small cell carcinoma of the esophagus (SCCE) is one of the deadliest aggressive cancers with poor prognosis (62).

It accounts for 1–2.8% of all esophageal carcinomas. Most diagnosed patients with SCCE die within 2 years and survival rates range between 8–13 months (63). Histologically, SCCE is similar to SCC that arises in the lung and other extra-pulmonary organs. It is characterized by neuroendocrine-like architectural patterns, including nested and trabecular growth with common characteristics including peripheral palisading and rosette formation (64). Understanding the pathogenesis of SCCE is urgently required to develop new diagnostic tools and effective treatment for this deadly cancer. Genetic alterations in exon 8 are shown in Table 6 (Appendix 2).

The missense mutation K305M is located within a stretch of residues, bipartite nuclear localization signal, which is annotated as a special motif in UniProt (N6-acetyllysine). This mutation may disturb the motif and probably affect its function (39, 65). Moreover, this mutation matches a previously described variant implicated in a familial cancer not matching LFS, germline mutation and somatic mutation (39). A silent mutation at position 305 is also reported by Rihab *et al.* in Sudanese patients who were diagnosed with esophageal squamous cell carcinoma (66).

In patient 18, we found missense mutation of a Lysine into a Threonine at position 291. This residue is located in a domain which is important for binding of other molecules and in contact with residues in a domain that is also important for binding (DNA binding site GO:0003677 and DNA-Binding Transcription Factor Activity GO:0003700). The mutation might disturb the interaction between these two domains and consequently affect the function of the *TP53* protein (39). Moreover, this mutation is located in a region with known splice variants, described in sporadic cancers and somatic mutation (dbSNP: rs372613518 and dbSNP: rs781490101) corresponds to variant. Additionally, mutagenesis experiments have been performed on this position and the next (291 and 292). Mutation of the wild-type residues (KK) into (RR) abolishes polyubiquitination by Makorin Ring Finger Protein 1 (MKRN1) (67). Also, patient 18 had a silent mutation at position 285. A germline mutation and somatic mutation in this position implicated with Li-Fraumeni syndrome (LFS) (OMIM:151623). Further studies with large sample size are required to demonstrate the usefulness of these mutations in the screening of EC especially SCCE. Studying the genetic alteration of esophageal

carcinoma will help in the development of new diagnostic and therapeutic tools for its treatment.

In conclusion, we found a significant association between the over expression and an accumulation of *TP53* protein and mutations in exon 4 and 8. Also, there is a significant association between esophageal carcinoma and the Pro72 variant of the Pro72Arg polymorphism of the *p53* gene. A silent mutation *P301P* was detected in all of examined cases. Two patients who were diagnosed with small cell sarcoma have shared the same mutations in exon8.

## References

1. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. *Journal of surgical oncology*. 2017;115(5):564-79.
2. Zhang Y. Epidemiology of esophageal cancer. *World journal of gastroenterology*. 2013;19(34):5598-606.
3. Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M, et al. The incidence and mortality of esophageal cancer and their relationship to development in Asia. *Annals of translational medicine*. 2016;4(2):29.
4. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. *Gastroenterol Clin North Am*. 2009; 38 (1):27-57, vii.
5. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 1990; 87(24):9958-61.
6. Romero Y. Familial association in barrett esophagus. *Gastroenterol Hepatol (N Y)*. 2007;3(5):346-8.
7. Asma Mahir Hamad MEKA, Abdulfattah Abdelgadir, Ikhlas B. Suliman. Esophageal Cancer in Sudan: Demographic and Histopathological Variations. *Open Journal of Gastroenterology*. 2017;7(3):124-9.
8. Steccanella F, Costanzo A, Petrelli F. Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al. *Journal of thoracic disease*. 2017;9(6):1450-2.
9. Fang J, Jaspersen K. Germline APC Mutation and Familial Barrett Esophagus: Causal or Coincidence? *Gastroenterol Hepatol (N Y)*. 2011;7(5):342-4.
10. Beely MABI AH, Aziz MSAE, ALmutlaq BA, Alturkstani MZ. Esophageal Cancer in the Sudan: Focus on the Screening for EBV and the Surgical Management. *MOJ Surg* 2017;4(6):00092.

11. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000; 100 (1):57-70.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144 (5):646-74.
13. Zhao L, Zhao X, Wu X, Tang W. Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. *Genetic testing and molecular biomarkers*. 2013; 17(10):721-6.
14. Weinberg RA. *The Biology of Cancer*: Garland Science; 2014. 231 p.
15. Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. *Journal of biomedicine & biotechnology*. 2012; 2012:891961.
16. Vos M, Adams CH, Victor TC, HeldenPDv. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. *Cancer genetics and cytogenetics*. 2003; 140(2003):23-30.
17. Chen J, Wu F, Pei HL, Gu WD, Ning ZH, Shao YJ, et al. Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer. *Oncology letters*. 2015; 10(4):2197-203.
18. Peng JZ, Xue L, Liu DG, Lin YH. Association of the p53 Arg72Pro polymorphism with esophageal cancer in Chinese populations: a meta-analysis. *Genetics and molecular research: GMR*. 2015; 14(3):9024-33.
19. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourougaa K, Vojtesek B, et al. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. *Oncogene*. 2006; 25(52):6936-47.
20. Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in Kras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013; 34(3):1901-11.
21. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. *Molecular and cellular biology*. 1999; 19(2):1092-100.
22. Eltahir H, Adam A, Yahia Z, Ali N, M Mursi D, M Higazi A, et al. p53 Codon 72 arginine/proline polymorphism and cancer in Sudan 2012.

23. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? *Pharmacogenetics and genomics*. 2007; 17(8):639-45.
24. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, et al. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. *International journal of cancer*. 2009; 125(12):2903-11.
25. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. *International Journal of Cancer*. 2011; 129(4):920-30.
26. Boulos PB, El Masri SH. Carcinoma of the oesophagus in the Sudan. *Trop Geogr Med*. 1977; 29(2):150-4.
27. Mohammed ME, Abuidris DO, Elgaili EM, Gasmelseed N. Predominance of females with oesophageal cancer in Gezira, Central Sudan. *Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology*. 2012; 13(4):174-7.
28. El Hassan A, El Hassan L, Mudawi H, Gasim B, Own A, Elamin E, et al. Malignant gastric tumors in Sudan: a report from a single pathology center. *Hematol Oncol Stem Cell Ther*. 2008; 1(2):130-2.
29. T c, R S, S H. A simple method for DNA purification from peripheral blood. *Analytical Biochemistry*. 1988; 174(2):485-8.
30. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. *Journal of the National Cancer Institute*. 2002; 94(9):681-90.
31. FinchTV. 1.4.0 ed. USA: Geospiza, Inc.; Seattle, WA; 2012.
32. Altschul SF, Madden TL, Schäffer AA, J Zhang ZZ, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST. A new generation of protein database search programmes. *Nucleic Acids Res*. 1997; 25(17):3389-402.
33. Carr IM CN, Taylor GR, Charlton R, Ellard S, Sheridan EG, Markham AF, BonthronDT. GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms. *Journal of medical genetics*. 2011; 48(2):123-30.
34. Lowe TM, Eddy SR. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic acids research*. 1997; 25(5):955-64.

35. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucl Acids Symp Ser* 1999; 41:95-8.
36. ExPASy translate tool [cited 2017 8 Dec]. Available from: <http://web.expasy.org/translate>.
37. Ng PC HS. SIFT: predicting amino acid changes that affect protein function. *Nucleic acids research*. 2003; 31(13):3812-4.
38. Lin HH, Huang HP, Huang CC, Chen JH, Wang CJ. Hibiscus polyphenol-rich extract induces apoptosis in human gastric carcinoma cells via p53 phosphorylation and p38 MAPK/FasL cascade pathway. *Molecular carcinogenesis*. 2005; 43(2):86-99.
39. Venselaar H, TeBeek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics*. 2010; 11:548.
40. Capriotti E FP, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. *Nucleic acids research*. 2005; 33(Web Server issue):W306-10.
41. Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. *Bioinformatics (Oxford, England)*. 2006; 22(22):2729-34.
42. Wang S LW, Liu S, Xu J. RaptorX-Property: a web server for protein structure property prediction. *Nucleic acids research*. 2016; 44(W1):W430-W5.
43. Pettersen EF GT, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. *Journal of computational chemistry*. 2004; 25(13):1605-12.
44. Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. *World journal of gastroenterology*. 2010; 16(45):5669-81.
45. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, et al. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. *The Annals of thoracic surgery*. 2012; 93(4):1101-6.
46. Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G, et al. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing. *Cancer genomics & proteomics*. 2016; 13(3):231-8.
47. Ribeiro U, Jr., Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, et al. p53 sequence analysis

predicts treatment response and outcome of patients with esophageal carcinoma. *Cancer*. 1998; 83(1):7-18.

48. Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Shah V, Baxter JN, et al. Characterization of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. *Br J Cancer*. 2003; 89(9):1729-35.

49. Vos M, Adams CH, Victor TC, van Helden PD. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. *Cancer genetics and cytogenetics*. 2003; 140(1):23-30.

50. Kaur S, Sambyal V, Guleria K, Manjari M, Sudan M, Uppal MS, et al. Analysis of TP53 polymorphisms in North Indian sporadic esophageal cancer patients. *Asian Pacific journal of cancer prevention: APJCP*. 2014; 15(19):8413-22.

51. Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2006; 15(2):294-300.

52. Hu N, Li WJ, Su H, Wang C, Goldstein AM, Albert PS, et al. Common genetic variants of TP53 and BRCA2 in esophageal

cancer patients and healthy individuals from low and high risk areas of northern China. *Cancer detection and prevention*. 2003; 27(2):132-8.

53. Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, et al. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. *Journal of gastroenterology and hepatology*. 2013; 28(9):1482-8.

54. Yang J, Liu B, Li W, Xiong H, Qiu H, Fu Q, et al. Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC). *Cancer epidemiology*. 2013; 37(5):629-33.

55. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, et al. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2009; 15(9):31039.

56. Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, et al. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal

adenocarcinoma. *Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus*. 2010; 23(1):36-9.

57. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, et al. p53 polymorphism in human papillomavirus-associated esophageal cancer. *Cancer research*. 2000; 60(11):2753-5. 58.

58. Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yoon JY, et al. p53 codon 72 polymorphism and the risk of esophageal cancer: a Korean case-control study. *Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus*. 2011; 24(8):596-600.

59. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. *Cancer Lett*. 2002; 181(1):81-5.

60. Pantelis A, Pantelis D, Ruummele P, Hartmann A, Hofstaedter F, Buettner R, et al. p53 Codon 72 polymorphism, loss of heterozygosity and high-risk human papillomavirus infection in a low-incidence German esophageal squamous cell carcinoma patient cohort. *Oncology reports*. 2007; 17(5):1243-8.

61. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. *Cancer research*. 2009; 69(7):2956-65.

62. Hosseini S, Salek R, Nasrolahi H, Mohammadianpanah M, Judi M. Small Cell Carcinoma of the Esophagus: Clinicopathological Features and Outcome of 22 Cases. *Iranian Red Crescent medical journal*. 2015; 17(11):e20353-e.

63. Wang F, Liu D-B, Zhao Q, Chen G, Liu X-M, Wang Y-N, et al. The genomic landscape of small cell carcinoma of the esophagus. *Cell Research*. 2018; 28(7):771-4.

64. Yun J-P, Zhang M-F, Hou J-H, Tian Q-H, Fu J, Liang X-M, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. *BMC cancer*. 2007; 7:38-.

65. Reed SM, Quelle DE. P53 Acetylation: Regulation and Consequences. *Cancers*. 2014; 7(1):3069.

66. M. Elfaki R, S. Abdelaziz M, Altayb H, M. Munsoor M, A. Gameel A. Molecular and insilicoanalysis of single nucleotide polymorphism targeting human TP53 gene

exon 5-8 in Sudanese esophageal cancer patients 2018. 1741 p.

67. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, et al. Differential regulation of p53 and p21 by MKRN1 E3

ligase controls cell cycle arrest and apoptosis. The EMBO journal. 2009;28(14):2011-13.

**Appendix 1****Table 5:** Summary of published studies on Pro72Arg polymorphism in esophageal carcinoma in different populations

<b>Populations</b>	<b>Screening method</b>	<b>Inference</b>	<b>Reference</b>
<b>Sudanese</b>	RFLP-PCR DNA sequencing	↑ risk with PP genotype	Present study
<b>Sudanese</b>	PCR	↑ risk with RP genotype	(42)
<b>South African</b>	PCR-SSCP DNA sequencing	↑ risk with R allele	(43)
<b>North Indian</b>	PCR-RFLP	↑ risk with RP genotype	(44)
<b>Chinese</b>	PCR-RFLP	↑ risk with PP genotype	(45)
<b>Chinese</b>	PCR-SSCP DNA sequencing	No association	(46)
<b>Chinese</b>	PCR-RFLP	↑ risk with PP genotype	(47)
<b>Chinese</b>	TaqMan assay	↑ risk with RR and RP genotype	(48)
<b>Caucasian</b>	TaqMan assay	↑ risk with PP genotype	(49)
<b>American</b>	TaqMan assay	No association	(50)
<b>European and Asian</b>	Sequencing	↑ risk with RR genotype	(51)
<b>Korean</b>	Real Time PCR	↑ risk with P allele	(52)
<b>Japanese</b>	PCR	No association	(53)
<b>German</b>	PCR DNA sequencing	↑ risk with R allele and HPV infection	(54)
<b>European</b>	APEX	No association	(55)

## Appendix 2

**Table 6:** Genetic alterations of exon 8 in esophageal carcinoma patients

Patient No.	Type of carcinoma	Codon	Base change	Event	Mutation Amino-acid substitution
<b>Patient 18</b>	Small cell carcinoma	921	AAG →ACG	Transition	Lys →Thr
		301	CCA →CCC	Transition	Pro →Pro
		302_303	GGG_Ins T_	Frameshift*	GlySer →Gly Stop codon
		305	AGC		Lys →Met
			AAG →ATG	Transversion	
<b>Patient 19</b>	Small cell carcinoma	301	CCA →CCC	Transition	Pro →Pro
<b>Patient 20</b>	Squamous cell carcinoma	301	CCA →CCC	Transition	Pro →Pro
<b>Patient 21</b>	Small cell carcinoma	301	CCA →CCC	Transition	Pro →Pro
		302_303	GGG_Ins T_	Frameshift*	GlySer →Gly Stop codon
		305	AGC		Lys →Met
				AAG →ATG	Transversion
<b>Patient 24</b>	Adenocarcinoma	301	CCA →CCC	Transition	Pro →Pro

\* Novel mutation found in this work